Lexaria Bioscience
LEXX
25 hedge funds and large institutions have $1.17M invested in Lexaria Bioscience in 2026 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
25% more funds holding
Funds holding: 20 → 25 (+5)
11% more capital invested
Capital invested by funds: $1.05M → $1.17M (+$114K)
0.11% less ownership
Funds ownership: 0.51% → 0.4% (-0.11%)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$54K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$18.2K |
| 3 |
Vontobel Holding
Zurich,
Switzerland
|
+$16.7K |
| 4 |
HF
HRT Financial
New York
|
+$13.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$224K |
| 2 |
BAM
Byrne Asset Management
Kingston,
New Jersey
|
-$76K |
| 3 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$20.8K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.15K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$126 |
LEXX Hedge Fund Activity: Q1 2026 in Review
25 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q1 2026, worth a combined $1.17M — up 11% from $1.05M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new LEXX positions and 3 closed out — a net gain of 6 holders — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $54K. The largest seller was UBS Group, cutting an estimated $224K.
- 25 institutional investors held Lexaria Bioscience (LEXX) as of Q1 2026, up from 20 in Q4 2025.
- Funds reported $1.17M of Lexaria Bioscience stock for Q1 2026, up 11% quarter-over-quarter.
- 9 funds opened new Lexaria Bioscience positions in Q1 2026 and 3 closed out, a net change of +6 holders.
- The largest Lexaria Bioscience buyer in Q1 2026 was Geode Capital Management, an estimated $54K added.
- The largest Lexaria Bioscience seller in Q1 2026 was UBS Group, an estimated $224K sold.
Based on aggregated 13F filings for Q1 2026.